AVITA Medical, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RCEL research report →
Companywww.avitamedical.com
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo.
- CEO
- Cary G. Vance
- IPO
- 2012
- Employees
- 260
- HQ
- Valencia, CA, US
Price Chart
Valuation
- Market Cap
- $107.32M
- P/E
- -29.10
- P/S
- 1.48
- P/B
- -56.95
- EV/EBITDA
- -8.23
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 81.36%
- Op Margin
- -19.12%
- Net Margin
- -62.67%
- ROE
- 305.45%
- ROIC
- 91.43%
Growth & Income
- Revenue
- $71.61M · 11.45%
- Net Income
- $-48,587,000 · 21.44%
- EPS
- $-1.74 · 27.20%
- Op Income
- $-41,934,000
- FCF YoY
- 44.74%
Performance & Tape
- 52W High
- $7.12
- 52W Low
- $3.22
- 50D MA
- $4.36
- 200D MA
- $4.35
- Beta
- 1.90
- Avg Volume
- 244.67K
Get TickerSpark's AI analysis on RCEL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 19, 26 | O'Toole David D | buy | 2,000 |
| Mar 11, 26 | O'Toole David D | buy | 1,800 |
| Jan 1, 26 | Woody Joseph Fralin | other | 0 |
| Feb 19, 26 | O'Toole David D | buy | 3,000 |
| Feb 18, 26 | O'Toole David D | other | 155,510 |
| Feb 18, 26 | O'Toole David D | other | 105,470 |
| Feb 18, 26 | KELSEY NICOLE | other | 145,060 |
| Feb 18, 26 | KELSEY NICOLE | other | 98,390 |
| Aug 28, 25 | McNamara Robert | buy | 10,000 |
| Aug 26, 25 | O'Toole David D | buy | 2,000 |
Our RCEL Coverage
We haven't published any research on RCEL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RCEL Report →